Arca
Skip to content
Tools
Tools

-anib

An angiogenesis inhibitor, blocking the growth of new blood vessels that tumours need.

  • Drugs ending in -anib: 28
  • Approved somewhere: 5
  • With a US drug page: 4

What it means

Stem from WHO's stem book, 2024; description by Arca
Stem
-anib
Class
Drugs that stop tumours growing new blood vessels

Drugs that carry it

Approved and clinical-stage drugs in ChEMBL whose names ending in -anib, matched by spelling; those with a US drug page link to it.
Acts on
PazopanibApprovedCSF1R, KIT, LCK, FGFR3 and 4 moreMacrophage colony stimulating factor receptor inhibitor
Pegaptanib sodiumApprovedVEGFAVascular endothelial growth factor A antagonist
TivozanibApprovedVascular endothelial growth factor receptor, KIT, PDGFRBVascular endothelial growth factor receptor inhibitor
VandetanibApprovedSRC, PTK6, TEK, Vascular endothelial growth factor receptor and 3 moreTyrosine-protein kinase SRC inhibitor
NintedanibApprovedPDGFRA, PDGFRB, Vascular endothelial growth factor receptor, Fibroblast growth factor receptorPlatelet-derived growth factor receptor inhibitor
BeloranibPhase 3METAP2Methionine aminopeptidase 2 inhibitor
BevasiranibPhase 3VEGF-A mRNA, TLR3VEGF-A mRNA RNAi inhibitor
BrivanibPhase 3Fibroblast growth factor receptor, Vascular endothelial growth factor receptorFibroblast growth factor receptor inhibitor
Brivanib alaninatePhase 3Fibroblast growth factor receptor, Vascular endothelial growth factor receptorFibroblast growth factor receptor inhibitor
CediranibPhase 3KIT, PDGFRA, PDGFRB, Vascular endothelial growth factor receptorStem cell growth factor receptor inhibitor
CrenolanibPhase 3PDGFRA, PDGFRB, FLT3Platelet-derived growth factor receptor inhibitor
LinifanibPhase 3CSF1R, FLT3, PDGFRA, PDGFRB, Vascular endothelial growth factor receptorMacrophage colony stimulating factor receptor inhibitor
MotesanibPhase 3KIT, RET, Vascular endothelial growth factor receptor, PDGFRA, PDGFRBStem cell growth factor receptor inhibitor
Pegaptanib octasodiumPhase 3VEGFAVascular endothelial growth factor A inhibitor
Pegpleranib sodiumPhase 3PDGFBPlatelet-derived growth factor subunit B inhibitor
RivoceranibPhase 3KDRVascular endothelial growth factor receptor 2 inhibitor
SemaxanibPhase 3KIT, Vascular endothelial growth factor receptorStem cell growth factor receptor inhibitor
TrebananibPhase 3ANGPT1, ANGPT2Angiopoietin-1 inhibitor
VatalanibPhase 3KIT, PDGFRA, PDGFRB, Vascular endothelial growth factor receptor, CSF1RStem cell growth factor receptor inhibitor
FoslinanibPhase 2——
LucitanibPhase 2FGFR1, Vascular endothelial growth factor receptor, FGFR2Fibroblast growth factor receptor 1 inhibitor
PegdinetanibPhase 2KDRVascular endothelial growth factor receptor 2 inhibitor
RisuteganibPhase 2——
VorolanibPhase 2——
AlofanibPhase 1——
MigaldendranibPhase 1——
NecuparanibPhase 1——
Toceranib—KDR, PDGFRB, KITreceptor protein-tyrosine kinase inhibitor

Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.